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Abstract
Encephalitis is caused by a variety of conditions, including infections of the brain by a wide range of pathogens. A substantial number of
cases of encephalitis defy all attempts at identifying a speciﬁc cause. Little is known about the long-term prognosis in patients with
encephalitis of unknown aetiology, which complicates their management during the acute illness. To learn more about the prognosis
of patients with encephalitis of unknown aetiology, patients in whom no aetiology could be identiﬁed were examined in a large, single-
centre encephalitis cohort. In addition to analysing the clinical data of the acute illness, surviving patients were assessed by telephone
interview a minimum of 2 years after the acute illness by applying a standardized test battery. Of the patients with encephalitis who
qualiﬁed for inclusion (n = 203), 39 patients (19.2%) had encephalitis of unknown aetiology. The case fatality in these patients was
12.8%. Among the survivors, 53% suffered from various neurological sequelae, most often attention and sensory deﬁcits. Among the
features at presentation that were associated with adverse outcome were older age, increased C-reactive protein, coma and a high
percentage of polymorphonuclear cells in the cerebrospinal ﬂuid. In conclusion, the outcome in an unselected cohort of patients with
encephalitis of unknown aetiology was marked by substantial case fatality and by long-term neurological deﬁcits in approximately
one-half of the surviving patients. Certain features on admission predicted an unfavourable outcome.
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Introduction
Encephalitis is a clinical syndrome characterized by central
nervous symptoms such as headache, mental status change,
neurological deﬁcits, seizures and fever [1]. The disease rep-
resents a signiﬁcant burden in terms of morbidity, mortality
and healthcare costs [2,3].
Encephalitis-like illnesses are caused by several pathogeni-
cally distinct mechanisms, including infections, post-infectious
immune reactions, other inﬂammatory processes, paraneo-
plastic conditions and intoxications [4,5]. Despite consider-
able progress in imaging techniques and the detection of
microbial pathogens, diagnostic efforts fail to identify an
aetiological agent in many patients with encephalitis [6,7].
Consequently, clinicians commonly care for patients with
encephalitis of unknown aetiology for prolonged periods of
time.
Treatment options for patients with encephalitis are lim-
ited. Antiviral drugs that are typically used to empirically
treat patients with encephalitis of unknown aetiology cover
only a small spectrum of the potentially involved viruses (i.e.
herpes viruses). Many patients are treated with other phar-
macological agents, such as corticosteroids, in addition to
anti-epileptic drugs indicated in patients with evidence of sei-
zures [1]. The uncertainty regarding the aetiology and prog-
nosis in these patients hampers the optimal management and
represents a major burden for the patients themselves as
well as those who care for them [8].
Little is known regarding the outcome and especially the
long-term neurological outcome of patients with encephalitis,
in whom no aetiological diagnosis can be established [9]. In
the present study, we therefore assessed the long-term out-
come in a retrospectively identiﬁed cohort of consecutive
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patients with encephalitis, in whom no aetiology could be
identiﬁed at the time of hospitalization. Speciﬁcally, we
assessed the health status, including the presence of perma-
nent neurological sequelae and the daily performance of the
surviving patients by structured telephone interviews for a
minimum of 2 years after discharge from hospital. Further-
more, we examined which clinical and laboratory parameters
at the time of admission were signiﬁcantly associated with an
unfavourable outcome (deﬁned as death or long-term func-
tional impairment). Finally, we assessed how many of the
patients in our collective presented with one of the ten
characteristic clinical proﬁles of encephalitis as recently
proposed by the investigators of the California Encephalitis
Project [5].
Materials and Methods
The study was approved by the institutional review board
(KEK) of the Kanton of Bern, Switzerland. The study popula-
tion consisted of patients who had a clinical diagnosis of
encephalitis and in whom diagnostic studies had failed to
identify an aetiological cause of their disease. Patients hospi-
talized between the years 1992 and 2004 in the Department
of Neurology, University Hospital Inselspital, Bern, were ret-
rospectively identiﬁed based on the Hospital records. In a
ﬁrst step, all patients were identiﬁed in whom the neurologi-
cal diagnosis code of discharge during the study period indi-
cated any form of encephalitis (n = 267). Insufﬁcient
information was available for 35 of these patients, leaving
232 patients for further study. Next, a review to conﬁrm the
aetiological diagnosis was performed in all patients who were
discharged with a code indicating a speciﬁc aetiology or a
clearly-deﬁned clinical syndrome (n = 83). The charts of the
remaining patients (n = 149) were examined in detail to
determine their eligibility for the outcome study of patients
with encephalitis of unknown aetiology.
To be included in the outcome study of a patient with
encephalitis of unknown aetiology, the following inclusion cri-
teria had to be met: signs and symptoms of encephalitis/
encephalopathy with quantitative or qualitative impairment of
level of consciousness for more than 24 h duration and
at least one of the following signs or symptoms: body temper-
ature of >38.0C, seizure, focal neurological signs, cerebro-
spinal ﬂuid (CSF) pleocytosis, or neuroradiological or
neurophysiological signs of encephalitis. Exclusion criteria
were: (i) age <16 years; (ii) start of symptoms >3 weeks
before hospitalization; (iii) HIV infection; (iv) chronic inﬂam-
matory systemic disease or neoplasia; (v) abuse of intravenous
drugs or alcohol; (vi) a diagnosis of migraine with aura; (vii)
residence in Switzerland for <6 months before beginning of
symptoms; and (viii) proven or probable infectious or non-
infectious aetiology of encephalitis. With this selection proce-
dure, a total of 39 patients with a diagnosis of acute encephali-
tis of undetermined aetiology were retained for further
analysis. All relevant data were extracted from the charts
and radiology and laboratory reports and entered into a
database.
For the assessment of long-term outcome, patients were
contacted by telephone between 2006 and 2007 and were
asked to provide their informed consent for participation in
the study. Using a standardized questionnaire, residual neu-
rological symptoms and their impact on the patient’s daily
activities were queried. In addition, four standardized tests
were performed: (i) a six-item orientation memory concen-
tration test [10]; (ii) a questionnaire for attention deﬁcits
[11]; (iii) the short version of the Geriatric Depression Scale
[12]; and (iv) the Epworth Sleepiness Scale [13].
Outcome was deﬁned as ‘healed’ if the patient was alive,
there were no signs and symptoms of encephalitis, and the
neuropsychological test results were normal. ‘Deﬁcit’ was
deﬁned as any abnormal neuropsychological test result or
overt neurological deﬁcit. Death was categorized based on
clinical judgement as either the result of encephalitis or unre-
lated causes.
Statistical analysis was performed with sTATvIEW, version
5.0 (SAS Institute Inc., Cary, NC, USA). Proportions were
compared with the chi-square test or Fisher’s exact test as
appropriate. Differences between means were assessed by
Student’s t-test. p £ 0.05 (two-tailed) was considered statisti-
cally signiﬁcant.
Results
Of the 149 patients with a discharge code that did not sug-
gest an obvious aetiology, sixteen were excluded because
they were <16 years old, and thirteen were excluded
because the diagnosis of encephalitis could not be conﬁrmed
based on the detailed chart review. Of the remaining 120
patients, 39 were classiﬁed as encephalitis of unknown origin
(Table 1) and constituted the study collective for this analy-
sis. For the other patients (n = 164), the proven or likely
aetiologies based either on discharge records (n = 83) or on
detailed chart reviews (n = 81) are shown in Table 1.
The patients in the study collective presented with a range
of symptoms typically seen in patients suffering from enceph-
alitis (Table 2) [5]. The average age was 47 years and males
predominated slightly (56%). Approximately one-half (53%)
of patients had prodromal symptoms, most often fever (43%)
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or respiratory symptoms (25%). The mean delay from onset
of neurological symptoms to referral was 9 days. Almost
one-third of patients presented with seizures, but only 12%
were comatose at presentation. All but two patients had ele-
vated white blood cells in the CSF, with a mean cell count of
74 per mm3 and a clear predominance of mononuclear cells.
CSF protein levels were elevated in two-thirds of patients
(n = 30), whereas glucose level was mostly in the normal
range (n = 37). Only one-ﬁfth of patients had a C-reactive
protein (CRP) level >20 mg/dL (normal value <5 mg/dL).
Cases clustered in the months of January to June with 26 of
39 cases (74%).
Clinical classiﬁcation
Only 11 of 39 patients with encephalitis of unknown aetiol-
ogy presented with one of the ten clinical proﬁles that have
been described by Glaser et al. [5] in their large cohort of
patients with encephalitis. Three patients presented with
temporal lobe involvement (proﬁle 1), two with cerebellar
involvement (proﬁle 3), three with primary seizures with
rapid recovery (proﬁle 7), two with psychosis (proﬁle 8),
and one with multifocal white matter lesions (proﬁle 10).
The clinical presentation of the other 28 patients did not
clearly ﬁt one of the ten proﬁles.
Outcome
Of the 39 patients, 34 (87.1%) were alive at the time of fol-
low-up, although two of the 34 patients who were still alive
could not be reached for interview. Five (12.8%) patients had
died with severe encephalopathy, two of them in the acute
phase of illness. Among the 32 patients who were available
for follow-up interviews, 15 (46.8%) patients were consid-
ered to be healed and 17 (53.1%) had neurological deﬁcits. A
wide range of symptoms was reported by the patients, with
the most frequent deﬁcits being attention and sensory deﬁ-
cits (Fig. 1).
Factors that were associated with death were older age,
comorbidity, coma at referral, low CSF white blood cell
count, higher percentage of polymorphonuclear cells in the
CSF, and a CRP value >20 mg/dL (Tables 3 and 4). Full
recovery was associated with relative young age, lack of
comorbidity, and presentation with minor focal neurological
deﬁcits but intact vigilance.
Discussion
The present study focussed on patients with a clinical diag-
nosis of encephalitis, in whom no aetiology could be
established. The rationale for this approach was based on
the fact that the management of these patients is particu-
larly challenging, not least because the prediction of out-
come is more uncertain than in patients with a known
aetiology of encephalitis. The results obtained show that,
in a large, unselected cohort of patients with encephalitis,
19.2% were classiﬁed as having encephalitis of unknown
origin. In these patients, mortality attributable to encephali-
tis was 13% and only one-half of the surviving patients
interviewed at least 2 years after the acute illness were
considered to be cured and free of long-term neurological
impairment.
Compared to the other series, the percentage of patients
in whom no aetiology could be identiﬁed was relatively low
TABLE 1. Diagnosis in 203 patients with encephalitis
Encephalitis with unknown aetiology 39 (19.2%)
Encephalitis with infectious aetiology 107 (52.7%)
Neuroborreliosis 20
Herpes simplex virus encephalitis 16
HIV-associated encephalopathy 13
Other viral encephalitis 6
Meningitis and brain abscess 9
Para- and post-infectious 15
Previous encephalitis 9
Other infectious 19
Non-infectious causes 57 (28.1%)
Acute demyelinating disease, multiple sclerosis 15
Sarcoidosis of the central nervous system 8
Tumour-associated/paraneoplastic 6
Vascular/migraine 5
Various others 23
TABLE 2. Characteristics of 39 patients with acute encepha-
litis of unknown aetiology
Total, n (%) 39 (100)
Age (years), mean ± SD 47.2 ± 16.6
Male gender, n (%) 22 (56.4)
Swiss nationality, n (%) 35 (89.7)
Travel abroad in last 4 weeks1, n (%) 4 (10.2)
Days from onset of illness to hospital admission, mean ± sd 8.8 ± 9.4
Admission to intensive care, n (%) 9 (23.0)
Prodrome (any), n (%) 21 (53.8)
Fever, n (%) 17 (43.5)
Respiratory symptoms, n (%) 10 (25.6)
Gastrointestinal symptoms, n (%) 5 (12.8)
Myalgia/arthralgia, n (%) 8 (20.5)
Rash, n (%) 1 (2.5)
Seizure, n (%) 11 (28.2)
Coma, n (%) 5 (12.8)
Death, n (%) 5 (12.8)
Days of hospital stay, mean ± SD 18.8 ± 18.2
CSF white blood cell count per mm3, mean ± sd 74.3 ± 74.4
CSF polymorphonuclear cells (%), mean ± SD 15.4 ± 29.1
CSF protein level (mg/dL), mean ± sd 1.0 ± 5.4
CSF glucose level (mmol/L), mean ± SD 3.2 ± 0.7
Initial abnormal neuroimaging, n (%) 19 (65.5)
Steroid treatment, n (%) 10 (25.6)
Days, mean ± sd 11.3 ± 13.2
Antiviral treatment, n (%) 29 (74.3)
Days, mean ± SD 8.0 ± 5.6
Antiepileptic treatment, n (%) 14 (35.8)
White blood cell count per mm3, mean ± sd 8.5 ± 3.9
Platelet count per mm3, mean ± SD 282 ± 85
C-reactive protein >20 mg/dL, n (%) 8 (20.5)
CSF, cerebrospinal ﬂuid.
1Spain, Tunisia, Malta, Thailand
CMI Schmidt et al. Outcome of encephalitis of unknown cause 623
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 621–626
in the present study (19%). For comparison, in the large,
prospective California Encephalitis Project (CEP), no aetiol-
ogy could be identiﬁed in 63% of the patients [5,6]. In a large
study from Finland, 41% of patients had no identiﬁed aetiol-
ogy [8], whereas, in a smaller study from the same country,
the aetiology could not be determined in 64% of 42 patients
with encephalitis [4]. The corresponding ﬁgure was 48% in a
similar study from Sweden [7]. Finally, a prospective study in
Taiwan failed to identify the aetiology in 31% of 124 enrolled
patients [14].
These differences likely reﬂect differences in the study
design, in the population of patients that were studied, the
local epidemiology of encephalitis, and the available method-
ology and stringency applied to the criteria for establishing
the cause of disease. The present study was based on an
unselected patient population in a large tertiary care hospital
in Switzerland, which had included patients since the early
1990s and was retrospective. By contrast, the CEP study,
which showed one of the highest percentages of patients
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FIG. 1. Long-term outcome. For assessment of long-term outcome,
patients were contacted by phone between 2006 and 2007. (a) Four
standardized tests were performed: a six-item orientation memory
concentration test [10], a questionnaire for attention deﬁcits [11],
the short version of the Geriatric Depression Scale [12], and the
Epworth Sleepiness Scale [13]. (b) Using a standardized question-
naire, residual and neurological symptoms, as well as their impact on
patients’ daily activities, were queried.
TABLE 3. Clinical characteristics of 37 patients with
encephalitis of unknown aetiology stratiﬁed according to
outcome
Healed Defect Death p
Total, n (%) 15 (100) 17 (100) 5 (100)
Age (years), mean ± sd 42.2 ± 17.1 47.0 ± 13.8 62.4 ± 19.2 0.02a
Male gender, n (%) 10 (66.6) 8 (47.0) 3 (60.0) NS
Comorbidity, any, n (%) 4 (26.6) 7 (41.1) 4 (80.0) 0.05b
Days to hospital admission,
mean ± SD
7.1 ± 6.5 10.4 ± 10.7 8.4 ± 13.1 NS
Intensive care, n (%) 1 (6.6) 4 (23.5) 3 (60.0) 0.01b
Prodrome, any, n (%) 10 (66.6) 6 (35.2) 3 (60.0) NS
Fever, n (%) 8 (53.3) 6 (35.2) 2 (40.0) NS
Minor focal deﬁcits without
mental status changes, n (%)
11 (73.3) 3 (17.6) 3 (60.0) 0.002c
Seizure, n (%) 5 (33.3) 4 (23.5) 1 (20.0) NS
Coma, n (%) 1 (6.6) 1 (5.8) 3 (60.0) 0.01a
Glasgow coma scale,
mean ± sd
13.3 ± 2.6 13.9 ± 2.6 7.6 ± 4.4 <0.001a
Days of hospital stay,
mean ± SD
12.0 ± 7.0 20.5 ± 16.9 45.5 ± 16.9 0.03a
Steroid treatment, n (%) 3 (20.0) 5 (29.4) 2 (40.0) NS
Antiviral treatment, n (%) 11 (73.3) 13 (76.4) 3 (60.0) NS
Antiepileptic treatment, n (%) 5 (33.3) 6 (35.2) 2 (40.0) NS
NS, nonsigniﬁcant.
Two of 39 patients were excluded because they were unavailable for interview
at follow-up.
aChi-square or Fisher’s exact test used for the comparison of patients who died
with those who survived.
bChi-square test for trend.
cChi-square test comparing all three groups with each other.
TABLE 4. Laboratory ﬁndings in 37 patients with encephali-
tis of unknown aetiology stratiﬁed according to outcome
Healed Defect Death p
Total, n (%) 15 (100) 17 (100) 5 (100)
CSF white blood cell count
per mm3, mean ± sd
85.8 ± 82.1 85.0 ± 77.2 23.0 ± 77.2 0.09a
CSF polymorphonuclear
cells (%), mean ± SD
10.9 ± 28.0 8.5 ± 14.3 47.0 ± 6.9 0.005a
CSF protein level (mg/dL),
mean ± sd
0.77 ± 0.64 21.4 ± 82.0 1.28 ± 1.75 NS
CSF glucose level (mmol/L),
mean ± SD
3.5 ± 0.82 3.1 ± 0.6 3.2 ± 0.5 NS
Abnormal neuroimaging, n (%) 6 (40.0) 7 (41.1) 3 (60.0) NS
White blood cell count
per mm3, mean ± sd
8.0 ± 3.5 8.8 ± 4.7 8.9 ± 2.3 NS
Platelet count per mm3,
mean ± SD
257 ± 45 292 ± 85 307 ± 171 NS
CRP >20 mg/dL, n (%) 0 (0) 2 (11.6) 5 (100) 0.02b
CSF, cerebrospinal ﬂuid; CRP, C-reactive protein; NS, nonsigniﬁcant.
Two of 39 patients were excluded, because they were unavailable for interview
at follow-up.
aChi-square or Fisher’s exact test used for the comparison of patients who died
with those who survived.
bChi-square test for trend.
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with unknown aetiology, represents a prospective collection
of CSF samples and patient data at a State reference labora-
tory. The selection of cases with this design likely favours
the selection of difﬁcult-to-diagnose cases. Furthermore, the
very strict criteria required for diagnosing the aetiology of
encephalitis in the present study contributed to the high rate
of unknown causes [5,6].
By contrast to the widely diverse rates of unknown
aetiologies, the spectrum of identiﬁed causes of encephali-
tis was quite similar between our study and previous stud-
ies [4–8,14,15]. As in most of these previous studies, the
biggest group of identiﬁed aetiologies in the present study
was viral infections (herpes simplex virus, varicella zoster
virus, and other neuropathic viruses). A second important
group consisted of infections with nonviral pathogens, such
as bacteria (in particular Borrelia encephalitis), whereas a
third group encompassed a wide range of non-infectious
or para-infectious causes, in particular demyelinating
disorders.
The focus of the present study was on outcome (i.e.
mortality and long-term sequelae). For the most part, the
available data regarding outcome in patients with encephali-
tis is derived from series of patients infected with one spe-
ciﬁc pathogen. The almost 100% mortality of rabies
represents the extreme spectrum of the disease. Infections
by herpes simplex virus, various ﬂaviviruses (e.g., Japanese
encephalitis) and paramyxoviruses (e.g. Nipah and Hendra
virus) are among the aetiologies that are associated with
mortality rates typically in excess of 10% [1,16–20]. Entero-
virus infection, on the other hand, generally leads to a rela-
tively mild illness with low mortality, even though some
serotypes such as enterovirus 71 can cause severe and fatal
illness [21]. Besides mortality, neurological sequelae are
common after encephalitis. Herpes simplex encephalitis is
well known for the often severe neurological deﬁcits, and
many other forms of encephalitis are also often associated
with debilitating neurological deﬁcits [19,22]. Deﬁcits range
from subtle neuropsychological impairment and memory
deﬁcits to severe sensomotor sequelae and chronic epileptic
seizures.
The present study conﬁrms the signiﬁcant morbidity and
mortality of encephalitis in a group of patients with unknown
aetiology. Importantly, the mortality attributable to acute
encephalitis was 13%, which is comparable to the current
mortality for herpes simplex encephalitis [23]. Equally impor-
tant, the surviving patients in the present study showed
remarkably high rates of chronic deﬁcits, in that only one-
half of them were considered to be completely recovered
years after the acute illness. Hokkanen and Launes [17] dem-
onstrated that neuropsychological deﬁcits tend to improve
rather than worsen after acute encephalitis. Thus, our
patients, who on average were re-examined several years
after their acute infection, most likely had even more severe
deﬁcits in the early phase after encephalitis. Thus, the short-
and long-term neurological outcome in patients with enceph-
alitis of unknown aetiology is characterized by a high rate of
persisting neurological sequelae.
We found that certain factors were prognostic for an
unfavourable outcome. These factors included advanced
age, increased CRP, a predominance of neutrophil granulo-
cyte in the CSF, and coma. Of note, the presence of mild
focal neurological deﬁcits with preserved vigilance was pre-
dictive of favourable outcome. Little is known from other
studies about the prognostic factors in encephalitis. In her-
pes simplex encephalitis, two predictors of adverse out-
come were found to be a high clinical severity score on
admission and a long delay of antiviral therapy [20]. In
children, young age, seizures, coma and documented
viral infection have been associated with poor outcome
[24,25]. A recent study from France also conﬁrmed age
and coma as factors associated with death [26]. Underlying
illnesses, sepsis, mechanical ventilation, and infection caused
by herpes viruses, Mycobacterium tuberculosis or Listeria
monocytogenes, were other adverse risk factors in this
study [26].
Glaser et al. [5] have identiﬁed ten clinical proﬁles, into
which approximately one-half of the 1570 patients in their
study could be categorized. For most proﬁles, the mortality
rate was approximately 10%, which is similar to the collec-
tive in the present study. However, two proﬁles were asso-
ciated with much higher mortalities (proﬁle 5 ‘diffuse
cerebral oedema’ and proﬁle 6 ‘intractable seizures’) [5],
whereas two other proﬁles [e.g. ‘cerebellar disease’ (proﬁle
3) and ‘seizures with rapid recovery’ (proﬁle 7)] showed
very low mortality rates (2% and 0%, respectively). We
attempted to categorize our patients into the ten proﬁles.
Only 11 of our 39 (28%) patients clearly ﬁt one of the
proﬁles, with ﬁve of them ﬁtting one of the two low-
mortality proﬁles (i.e. proﬁles 3 and 7), and none ﬁtting
the high mortality proﬁles. More prospective studies
are needed to assess the value of the described proﬁles for
the prediction of outcome in patients with encephalitis
of unknown aetiology.
In summary, the present study shows that patients with
encephalitis of unknown aetiology, as a group, suffer from
signiﬁcant mortality (approximately 13%) and long-term mor-
bidity (approximately 50%) with a wide range of deﬁcits.
Some clinical parameter on admission, in particular older
age, coma and elevated CRP, were associated with an
adverse outcome.
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